Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

ENTERA BIO LTD. (ENTX) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

ENTERA BIO LTD. (ENTX), most recent 12 months reported: revenue $0, net loss $17.03M, free cash flow -$10.96M. Latest balance sheet on file: liquid cash $11.31M, total debt $284K, net cash $11.03M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): CEL-SCI CORPORATION · Denali Therapeutics Inc. · ELOXX PHARMACEUTICALS, INC. · enGene Therapeutics Inc. · ESTRELLA IMMUNOPHARMA, INC. · EXOZYMES INC. · GREEN PLANET BIOENGINEERING CO., LTD. · GREENLAND MINES LTD

Stock screener

Watchlist